Therefore, any changes observed in blood flow measurements following a pharmacological challenge with psilocybin might simply reflect changes in vascular tone as opposed to neuronal activity. The authors clearly anticipated this confound, and added a control condition, measuring BOLD signals while the participants held their breath. Breath holding induces hypercapnia and vasodilatation, and allows the assessment of vascular reactivity on BOLD signals [8] . Importantly, breath hold-induced BOLD responses appeared unchanged following psilocybin infusion, suggesting that their results were not confounded by changes in vascular tone.
Carhart-Harris and colleagues [2] interpret their results in terms of a decrease in activity in critical 'hub' regions of the brain, specifically, the anterior and posterior cingulated cortex, and a loss of coordination between them, caused by the inhibitory effects of serotonin 2A receptor stimulation. This would trigger ''a state of unconstrained cognition''. Consistent with their findings, studies in rats have suggested that cortical local field potentials, which the BOLD signal is believed to reflect, are decreased following serotonin 2A receptor stimulation [9] . However, an earlier study [10] using positron emission tomography reported increased glucose metabolism following psilocybin administration, somewhat clouding the picture.
A second study from the same group [3] focused not on brain activity in the resting state, but studied BOLD signals while participants were cued to recall specific personal memories of positive events from their life. Not only were memories described as more vivid, emotional and positive following psilocybin infusion, but brain responses were enhanced in visual and auditory cortex during autobiographic recollection. These findings led to a somewhat different conclusion than the first study, namely that psilocybin focuses and enhances subjective and neural responses to autobiographical memory rather than resulting in a state of 'unconstrained cognition'. This stark difference between the two sets of experimental findings underscores the difficulty in comparing results from task-related fMRI, as in the second study [3] , in which the effects of an experimental condition are compared with a control condition, with those from relatively unconstrained resting-state fMRI.
On the basis of their results, Carhart-Harris and colleagues [2, 3] suggest that psilocybin may have potential efficacy in the treatment of depression, especially when combined with psychotherapy. This conjecture is based mainly on their observations of a reduction in resting-state cerebral blood flow in the anterior cingulate cortex, which is reliably hyperactive in the depressed state [11] . While a recent study [6] did report slightly lowered depression scores 6 months after psilocybin administration in terminally ill cancer patients, this study specifically excluded individuals with a recent major depressive episode. Therefore, it remains to be seen whether psilocybin might help to treat depression. However, given the administrative obstacles in conducting such a trial under current regulatory frameworks, it is unlikely that we will witness a return to the 1950s heyday of psychedelic psychotherapy any time soon. 1 Although many proteins are mutated and misregulated in cancers, a preponderance of evidence implicates Mad2 overexpression as a driver of chromosomal instability. Mad2 overexpression is particularly associated with cancers in which the Rb or p53 tumor suppressors have been inactivated [2, 3] . Inactivation of either Rb or p53 causes both Mad2 overexpression and CIN, and in both cases the CIN phenotype can be rescued by experimentally reducing Mad2 overexpression. Mad2 overexpression per se is sufficient to cause CIN in vitro and in vivo [4] . Moreover, Mad2 overexpression and concomitant CIN causes tumorigenesis in mice, even when induced transiently, and can increase rates of relapse after withdrawal of a primary driver oncogene such as KRAS [5] . The cellular mechanism by which Mad2 overexpression causes CIN, however, had not been directly investigated until now.
Mad2 is a central component of the mitotic checkpoint: it localizes to unattached kinetochores and forms part of the diffusible 'wait' signal that inhibits the Anaphase Promoting Complex [6] . Given Mad2's central function as a mitotic checkpoint protein, it would be natural to assume that Mad2 overexpression drives CIN by causing a defect in the mitotic checkpoint. The fitness of the mitotic checkpoint is defined by two features: the ability to generate sufficient wait signal to prevent anaphase until all chromosomes are attached (checkpoint signaling) and the ability to release this arrest and allow anaphase to proceed swiftly once the last chromosome has attached (checkpoint silencing). Defects in either of these aspects of the checkpoint could cause CIN. Mad2-overexpressing cells can maintain a long mitotic arrest in the presence of nocodazole, a spindle poison that prevents proper kinetochore-microtubule attachments, suggesting that Mad2 overexpression does not prevent checkpoint signaling [3] . The effect of Mad2 overexpression on checkpoint silencing has not been carefully measured, and remains an interesting question.
Independent [7] . When stabilizing factors are compromised or destabilizing factors are hyperactivated, kinetochores can fail to bind microtubules. Conversely, hyperstabilization of kinetochore microtubules increases erroneous attachments in metaphase, which cause lagging chromosomes at anaphase. Although lagging chromosomes are often successfully corrected [8] , they can cause cleavage furrow regression and consequent tetraploidization, or they can be pulverized by the cleavage furrow, leading to chromosome rearrangements [9] [10] [11] . The net microtubule-destabilizing activity can be experimentally determined from the overall rates of microtubule turnover in the spindle. Kinetochore-microtubule hyperstabilization in cancer cell lines strongly predicts lagging chromosomes at anaphase, and these defects can be rescued by expression of targeted destabilizing factors [12] . Thus, defects in kinetochore microtubule dynamics appear to be a common theme underlying the mechanisms of CIN in diverse cancers.
Kabeche and Compton [1] Having established that Mad2 overexpression causes CIN via the hyperstabilization of kinetochore microtubules, a natural candidate to investigate was Aurora B kinase, a key regulator of kinetochore-microtubule stability [13, 14] . Aurora B normally localizes to centromeres during prometaphase and metaphase and regulates kinetochore microtubules by phosphorylating substrates that interact directly with microtubules. Inhibition of Aurora B causes increased rates of lagging chromosomes, and centromere localization of Aurora B, in close proximity to its kinetochore substrates, is essential for its function. Kabeche and Compton [1] show that when Mad2 is overexpressed, Aurora B fails to localize to centromeres, and phosphorylation of a kinetochore substrate is reduced. These results argue that Mad2 overexpression exerts its influence on kinetochore-microtubule stability by disrupting the centromere localization of Aurora B kinase, but it remains to be shown that Aurora B localization is deranged in vivo in genuine Mad2-overexpressing cancers. It will be interesting to see how Aurora B localization and activity are affected by Mad2 depletion, as it is formally possible that Mad2 depletion might affect microtubule stability through a different pathway altogether.
The discovery that Mad2 can affect Aurora B localization opens up a new front in the larger effort to understand how Aurora B localization is regulated throughout the cell cycle. Aurora B is part of the Chromosome Passenger Complex (CPC) along with INCENP, Survivin, and Borealin. We now know that CPC localization to the inner centromere is determined by the coincidence of two histone modifications: the phosphorylation of H2A-Thr120 and H3-Thr3 by the kinases Bub1 and Haspin, respectively [15] [16] [17] . It will be interesting to determine whether Bub1 or Haspin localization, or activity, are affected by Mad2 levels. It was recently found that diploid, nontransformed cell lines can dynamically regulate CPC levels at individual centromeres in response to the microtubule attachment state, but this regulation fails in the cancer cell lines that have been examined [18] . The newly discovered connections between Mad2 and Aurora B in the larger context of CIN and cancer herald an exciting area for further exploration. 1 
